Difference between revisions of "PL Lodz Watala C"
From Bioblast
Purtschera (talk | contribs) |
|||
Line 1: | Line 1: | ||
{{MiPNetLab | {{MiPNetLab | ||
|address=Watala Cezary | |address=[[Watala C|Watala Cezary]], Prof. Dr. | ||
Department of Haemostasis | Department of Haemostasis and Haemostatic Disorders | ||
and Haemostatic Disorders | |||
Medical University of Lodz | Medical University of Lodz | ||
Line 9: | Line 8: | ||
113 Zeromskiego Street | 113 Zeromskiego Street | ||
90-549 ΕΓ³dΕΊ | 90-549 ΕΓ³dΕΊ, POLAND | ||
|city=Lodz | |city=Lodz | ||
|country=Poland | |country=Poland | ||
|MiPNetLab=Watala C, Labieniec M | |MiPNetLab=Watala C, Labieniec M | ||
|info= | |info=[http://www.oroboros.at/?IOC55-56 IOC55-56], [[IOC61]] | ||
}} | }} | ||
*Mitochondrial respiratory capacity nder normal and pathophysiological conditions (diabetes mellitu, atherothrombosis, brain-blood barrier disruption, cancerogenesis) | *Mitochondrial respiratory capacity nder normal and pathophysiological conditions (diabetes mellitu, atherothrombosis, brain-blood barrier disruption, cancerogenesis) | ||
*Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity | *Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity | ||
*targeting of biochemical and molecular burden of diabetes | *targeting of biochemical and molecular burden of diabetes |
Revision as of 13:11, 3 June 2012
- Mitochondrial respiratory capacity nder normal and pathophysiological conditions (diabetes mellitu, atherothrombosis, brain-blood barrier disruption, cancerogenesis)
- Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity
- targeting of biochemical and molecular burden of diabetes